– June 1, 2003
June 1, 2003
View Issues
-
Second Malignancies Following Adjuvant Chemotherapy
HEC, as delivered in this trial, cannot be recommended in clinical practice because of the lack of superiority over classic CMF and because of the increased risk of AML observed in this arm. Prolongation of conventional anthracycline-based treatment beyond the current standard of 4-6 cycles is not recommended in clinical practice. -
BRCA Mutations Associated with Improved Survival in Patients with Ovarian Cancer
In the current report, histological and biological features of ovarian cancer occurring in Jewish women were compared in the context of the presence or absence of BRCA mutations. -
10-Milligram Coumadin Loading for Outpatient Management of Deep-Vein Thrombosis
In this randomized outpatient clinical trial of anticoagulation nomograms for patients with acute deep-vein thrombosis, a 10-mg initial dose of warfarin (coumadin) proved superior to an initial 5-mg dose with regard to time reaching therapeutic INR. -
Carboplatin and Gemcitabine: Developing a More Gentle Approach for the Treatment of Advanced Transitional Cell Carcinoma
In the current report, fairly impressive results with carboplatin-gemcitabine chemotherapy used in patients with advanced transitional cell carcinoma are described. -
Trends in Incidence Rates of Invasive Lobular and Ductal Breast Carcinoma
Ductal carcinoma incidence rates remained essentially constant from 1987-1999 while lobular carcinoma rates increased steadily. This increase presents a clinical challenge given that lobular carcinoma is more difficult to detect than ductal carcinoma by both physical examination and mammography. -
Clinical Briefs in Primary Care Supplement